Gastric Cancer Registry Progress Spurs Five-Year, $9 Million NCI Grant
When the Gastric Cancer Foundation launched the Gastric Cancer Registry at Stanford University in 2011, our hope was that the patient samples... Read More
Going the Distance for a Cure
In November 2023, Ash Garcia Horn ran the Seattle Marathon. That, in itself, would be a story worth telling, but there is... Read More
National Campaign Launched to Help Patients Receive the Best Treatment
The Gastric Cancer Foundation is proud to be a Founding Supporter of Test Your Biomarkers, a national education and awareness campaign launched... Read More
2022 Seed Grant Recipient Dr. Nilay Sethi’s Team Reports Major Progress in Research
In 2022, the Gastric Cancer Foundation awarded a seed grant to Dr. Nilay Sethi to explore an innovative therapeutic approach for gastric... Read More
Grant Recipient Investigates New Approaches to Treatment-Resistant Complication
The Gastric Cancer Foundation is dedicated to bridging a significant funding gap for researchers focused on gastric cancer, especially those in the... Read More
Announcing $300,000 in Seed Grants to Fund Novel Research Studies
A primary obstacle encountered by researchers with new, promising strategies to combat gastric cancer is securing financial support for early-stage research. The... Read More
Foundation Research Scholar Lauds Funding as ‘Instrumental’ to Understanding of Peritoneal Spread
As Samuel J. Klempner, M.D. approaches the completion of his three years as a Ben Feinstein Memorial Research Scholar, he’s reporting promising... Read More
Gastric Cancer Registry Data Leads to New Discoveries
Data from the Gastric Cancer Registry at Stanford University Medical Center has led to important new discoveries, according to primary investigator Hanlee... Read More
New Research Scholar Martina Molgora Pursues Novel Target in Gastric Cancer
Shortly after she arrived at Washington University School of Medicine in St. Louis five years ago for her post-doctoral work, Martina Molgora,... Read More
Research Roundup: Engineered Nanoparticles and New Potential Standards of Care
Positive results from a phase 3 trial of Astellas Pharmaceuticals’ zolbetuximab and modified folinic acid, fluorouracil, and oxaliplatin (mFOLFOX6) “may represent a... Read More